Medjeral-Thomas NR, Lawrence C, Condon M, et al. - Researchers tested tacrolimus monotherapy without corticosteroids as a treatment option for patients with de novo minimal change disease in this multicenter, prospective, open-label, randomized, controlled trial. This inquiry included six nephrology units across the United Kingdom. Participants included adult patients with first presentation of minimal change disease and nephrotic syndrome. The participants were randomly assigned to either oral tacrolimus at 0.05 mg/kg twice daily, or prednisolone at 1 mg/kg daily up to 60 mg daily. The tacrolimus and prednisolone treatment cohorts did not differ significantly in terms of the proportion of patients in complete remission at 8 weeks, 16 weeks, or 26 weeks. Overall, tacrolimus monotherapy can afford an alternative option to treat patients wanting to avoid steroid treatment for minimal change disease.